713
Downloads
8
Episodes
Welcome to the “Pharm So Hard Ambulatory Care Podcast,” part of the “Pharm So Hard Network hosted by Micaela Hayes, PharmD and Morgan Grier, PharmD. This series is your go-to source for all things ambulatory care pharmacy. Join us as we explore medication therapy management, chronic disease management, innovative patient care models, and the latest in policy and practice updates. Featuring expert insights and real-world advice, our episodes are designed to empower pharmacy professionals to excel in outpatient care settings. Tune in to stay at the forefront of ambulatory care pharmacy practice and join a community of dedicated healthcare professionals committed to making a difference. Subscribe now and transform patient care with us.
Episodes
Tuesday Apr 30, 2024
Tuesday Apr 30, 2024
In this episode of the Pharm So Hard Ambulatory Care Podcast, the hosts discuss various studies and trials related to GLP-1 medications for weight management and cardiovascular outcomes. They provide updates on their personal lives and share their experiences with different vehicles, such as Jeeps and Broncos. The studies discussed include the Surmount 1 study, which showed significant weight loss in patients without diabetes; the Risk of Gastrointestinal Adverse Events Associated with GLP-1s study, which highlighted potential side effects of GLP-1 medications; the SELECT trial, which demonstrated the effectiveness of semaglutide in reducing cardiovascular events in patients with obesity and pre-existing cardiovascular disease; and a phase 2 trial of Retro-True Tide, a triple hormone receptor agonist that showed impressive weight loss results. The hosts also discuss the limitations and implications of these studies.
Takeaways
- GLP-1 medications have shown significant weight loss in patients without diabetes.
- GLP-1 medications may have gastrointestinal side effects, but the overall risk is small compared to the potential benefits.
- Semaglutide has been shown to reduce cardiovascular events in patients with obesity and pre-existing cardiovascular disease.
- Retro-True Tide, a triple hormone receptor agonist, has shown impressive weight loss results in a phase 2 trial.
- It is important to consider the limitations and implications of these studies when evaluating the use of GLP-1 medications.